
    
      This is a double blinded, placebo controlled trial. Patients who meet the inclusion criteria
      will be randomized to placebo or 25(OH)D3, 4,000 IU/d orally for 16 weeks. Enrolled patients
      will be tested for 24h-blood pressure, brachial arterial blood flow, vascular inflammatory
      markers and macrophage inflammatory response to modified-lipoproteins at baseline, middle and
      at the end of the study.
    
  